{
    "clinical_study": {
        "@rank": "110963", 
        "acronym": "AFTER-CV", 
        "arm_group": [
            {
                "arm_group_label": "Transesophageal Echocardiography group", 
                "arm_group_type": "Active Comparator", 
                "description": "This arm includes the patients with atrial fibrillation who undergo  transesophageal echocardiography-guided cardioversion"
            }, 
            {
                "arm_group_label": "Warfarin Group", 
                "arm_group_type": "Active Comparator", 
                "description": "This arm includes the patients with atrial fibrillation who take warfarin four weeks before electrical cardioversion."
            }
        ], 
        "brief_summary": {
            "textblock": "Patients with atrial fibrillation undergoing cardioversion will be randomized to undergo\n      transesophageal echocardiography or they will receive warfarin for 4 weeks with an\n      international normalized ratio (INR) value between 2.0-3.0.\n\n      If thrombus is detected in left atrium or in left atrial appendage, no cardioversion will be\n      performed. Other patients in the both groups will undergo electrical cardioversion. All\n      patients will have neurological examination and diffusion magnetic resonance imaging (MRI)\n      at baseline and at postprocedural 7th day. Clinical and subclinical cerebral thromboembolic\n      events detected by diffusion MRI will be recorded. Any bleeding events during this period\n      will also be recorded."
        }, 
        "brief_title": "Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Atrial Fibrillation", 
            "Cardioversion", 
            "Cerebrovascular Stroke"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Stroke", 
                "Cerebral Infarction", 
                "Thromboembolism"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with the age of more than 18 years who are planned to undergo electrical\n             cardioversion\n\n        Exclusion Criteria:\n\n          -  Urgent cardioversion\n\n          -  Patients who have implanted pace-makers or other metal devices\n\n          -  Claustrophobia\n\n          -  Hematological disorders enabling patients to receive anticoagulant agents\n\n          -  Atrial fibrillation secondary to temporary causes.\n\n          -  Serious rheumatic heart valve disease\n\n          -  Hyperthyroidism\n\n          -  History of malignancy\n\n          -  Left atrium diameter > 55 mm\n\n          -  Ejection fraction < 0.25"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01924065", 
            "org_study_id": "ozaydin291"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Transesophageal Echocardiography group", 
                    "Warfarin Group"
                ], 
                "intervention_name": "Cardioversion", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Warfarin Group", 
                "intervention_name": "warfarin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Warfarin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Atrial fibrillation, conversion, stroke", 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "contact": {
                "email": "adogan35@hotmail.com", 
                "last_name": "Abdullah Dogan, Proffesor,MD", 
                "phone": "+0902462324479", 
                "phone_ext": "1140"
            }, 
            "facility": {
                "address": {
                    "city": "Isparta", 
                    "country": "Turkey", 
                    "state": "Mediterranean Region", 
                    "zip": "32260"
                }, 
                "name": "Suleyman Demirel University"
            }, 
            "investigator": [
                {
                    "last_name": "Mehmet Ozaydin, Proffesor,MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "\u0130brahim Ersoy, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_arms": "2", 
        "official_title": "Does Cardioversion of Atrial Fibrillation Increase the Risk of Stroke and Silent Cerebrovascular Thromboembolism? Comparison of the Two Cardioversion Methods", 
        "overall_official": {
            "affiliation": "Suleyman Demirel University", 
            "last_name": "Mehmet Ozaydin, Proffesor,MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Turkey: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "ischemic or hemorrhagic strokes will be recorded", 
            "measure": "Stroke", 
            "safety_issue": "Yes", 
            "time_frame": "1 week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01924065"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Suleyman Demirel University", 
            "investigator_full_name": "Mehmet Ozaydin, MD", 
            "investigator_title": "MD, Professor in Cardiology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "silent cerebral thromboemboli detected by diffusion magnetic resonance imaging", 
                "measure": "silent cerebral thromboemboli", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "description": "Any bleeding", 
                "measure": "bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }
        ], 
        "source": "Suleyman Demirel University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Suleyman Demirel University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}